923
staff
Caitlin MacLean
Caitlin MacLean is senior director of innovative finance at the Milken Institute.
staff
Esther Krofah
Esther Krofah is the executive vice president of MI Health, leading FasterCures, Public Health, t
he Future of Aging, and Feeding Change.
+ Read More
staff
Kanika Singh
Kanika Singh is director of innovative finance at the Milken Institute.
staff
Ashley Campany
Ashley Campany is a senior associate on the Innovative Finance team at the Milken Institute. She
is responsible for research, development, execution, and follow-up for the Institute’s Financial Innovations Labs.
+ Read More
staff
Erika Stratmann
Erika Stratmann is the Director of Communications, Health. She is a mission-driven communica
tions and content development leader with more than a decade of experience advancing consumer education, community engagement and advocacy campaigns.
+ Read More
staff
Nicole Valentine
Nicole Valentine is the director, FinTech at the Milken Institute with over a decade of fina
ncial services, international mergers and acquisitions, technology, and innovation experience.
+ Read More
report
Strengthening the Biomedical Innovation Ecosystem: A Scorecard for System Assessment
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a
simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the
+ Read More
report
Cell and Gene Therapies: Looking Ahead to 2022
Cell and gene therapies are a new category of medicines transforming how we treat and potentially c
ure disease. Both cell and gene therapies seek to modify genetic material to fight disease.
+ Read More
report
Ghana’s Daakye Bond Program: An African Securitization Case Study
In Akan, the most widely spoken language in Ghana, daakye means future. It is an apt name, therefor
e, for the Daakye bond program, which invests in Ghana’s future leaders through securitizing future government tax flows.
+ Read More
report
Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem
Clinical trials have been used for decades as the primary way by which researchers determine if a n
ew treatment is safe and effective for human use.
+ Read More
report
COVID-19 Silver Linings for Biomedical Innovation: Implementation Roadmap
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical i
nnovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not think possible.
+ Read More